Document is current
Any future updates will be listed below
-
Authors
Wiklander, Oscar P. B. https://orcid.org/0000-0003-1176-8114
Mamand, Doste R.
Mohammad, Dara K. https://orcid.org/0000-0001-9201-0991
Zheng, Wenyi https://orcid.org/0000-0003-2416-5822
Jawad Wiklander, Rim
Sych, Taras
Zickler, Antje M. https://orcid.org/0000-0001-5001-6586
Liang, Xiuming
Sharma, Heena
Lavado, Andrea
Bost, Jeremy
Roudi, Samantha
Corso, Giulia https://orcid.org/0000-0002-1145-0862
Lennaárd, Angus J.
Abedi-Valugerdi, Manuchehr
Mäger, Imre https://orcid.org/0000-0003-2242-7227
Alici, Evren
Sezgin, Erdinc https://orcid.org/0000-0002-4915-388X
Nordin, Joel Z. https://orcid.org/0000-0002-3653-7710
Gupta, Dhanu
Görgens, André https://orcid.org/0000-0001-9198-0857
EL Andaloussi, Samir https://orcid.org/0000-0003-4468-9113
- License Information
-
More Information
Article History
Received: 20 March 2023
Accepted: 8 April 2024
First Online: 20 May 2024
Competing interests
: S.E.A. is a founder of and a consultant for Evox Therapeutics. D.G., J.Z.N. and A.G. are consultants for Evox Therapeutics. O.P.B.W., D.G., J.Z.N., A.G. and S.E.A. have stock interest in Evox Therapeutics. H.S. and A.L. are employees of Evox Therapeutics. The other authors declare no competing interests.
